{"entity":{"id":"nct03315364","kind":"trial","name":"Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy","aka":[],"tldr":"A phase 2/3 trial of Oral paclitaxel in advanced solid tumours, run by Daehwa Pharmaceutical Co., Ltd., active and no longer recruiting.","summary":"Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy is a phase 2/3 interventional study registered as NCT03315364 by Daehwa Pharmaceutical Co., Ltd., with 549 participants enrolled, started 2017-12-18 and due to reach its primary completion in 2024-02-19. Interventions recorded: Oral paclitaxel and Paclitaxel injection.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03315364","url":"https://clinicaltrials.gov/study/NCT03315364"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["daehwa-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03315364","phase":"2/3","setting":"A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel® (Oral Paclitaxel) Compared to Taxol® (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic HER2 Negative Breast Cancer","sponsor":"Daehwa Pharmaceutical Co., Ltd.","enrolled":549,"outcomes":[]},"route":"/trials/nct03315364/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"daehwa-pharmaceutical","kind":"company","name":"Daehwa Pharmaceutical","route":"/companies/daehwa-pharmaceutical/"}]}}